كندا - الإنجليزية - Health Canada

omega laboratories limited - naloxone hydrochloride (naloxone hydrochloride dihydrate) - solution - 0.4mg - naloxone hydrochloride (naloxone hydrochloride dihydrate) 0.4mg - opiate antagonists

كندا - الإنجليزية - Health Canada

omega laboratories limited - naloxone hydrochloride (naloxone hydrochloride dihydrate) - solution - 1mg - naloxone hydrochloride (naloxone hydrochloride dihydrate) 1mg - opiate antagonists

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

akorn - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 10 mg in 1 ml - hydromorphone hydrochloride injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. hydromorphone hydrochloride injection [high potency formulation (hpf)] is indicated for use in opioid-tolerant patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg oral morphine per day, or at least 25 mcg transdermal fentanyl per hour, or at least 30 mg oral oxycodone per day, or at least 8 g oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid for one week or longer. patients must remain on around-the-clock opioids while administering hydromorphone hydrochloride injection (hpf). lim

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 40 mg - oxycodone hcl extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve oxycodone hcl extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - oxycodone hcl extended-release tablets are not indicated as an as-needed (prn) analgesic oxycodone hcl extended-release tablets are contraindicated in patients with: - significant respiratory depression - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment - known o

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

sandoz inc - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 10 mg - oxycodone hcl extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use oxycodone hcl extended-release tablets are contraindicated in patients with: clinical considerations fetal/neonatal adverse reactions prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. observe newborns for symptoms of neonatal opioid withdrawal syndrome, such as poor feeding, diarrhea, irritability, tremor, rigidity, and seizures, and manage accordingly [see warnings and precautions (5.3)] . teratogenic effects - pregnancy category c there are no adequate and well-controlled studies in pregnant women. oxycodone hcl extended-release tablets should be used during pregnancy only if the potential benefit justifies the risk to the fetus.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

teva parenteral medicines, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 10 mg in 1 ml - hydromorphone hydrochloride injection [high potency formulation (hpf)] is indicated for use in opioid-tolerant patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg oral morphine per day, or at least 25 mcg transdermal fentanyl per hour, or at least 30 mg oral oxycodone per day, or at least 8 g oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid for one week or longer. patients must remain on around-the-clock opioids while administering hydromorphone hydrochloride injection [high potency formulation (hpf)]. limitations of use: because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)]

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

hospira, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 10 mg in 1 ml - hydromorphone hydrochloride injection [high potency formulation (hpf)] is indicated for use in opioid-tolerant patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg oral morphine per day, or at least 25 mcg transdermal fentanyl per hour, or at least 30 mg oral oxycodone per day, or at least 8 g oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid for one week or longer. patients must remain on around-the-clock opioids while administering hydromorphone hydrochloride injection [high potency formulation (hpf)]. limitations of use: because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [ see warnings and precautions (5.2)]

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists [e.g., methadone or laam (levo- alpha-acetyl-methadol)]. - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. - any individual with acute hepatitis or liver failure. naltrexone is a pure opioid antagonist. it does not lead to physical or p

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

precision dose inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists [e.g., methadone or laam (levo- alpha-acetyl-methadol)]. - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. - any individual with acute hepatitis or liver failure. naltrexone is a pure opioid antagonist. it does not lead to physical or p

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

avkare - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets usp are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone hydrochloride is a pure opioid antagonist. it does not lead to physical or psychological dependence. tolerance to the opioid antagonist effect is not known to occur.